What is Diamedix?
Diamedix, operating under the ImmunoVision brand, has established itself as a leader in the autoimmune market since 1985. The company specializes in supplying critical reagents for autoimmune research, offering a comprehensive portfolio that includes purified antigens, monoclonal and polyclonal antibodies, and disease state plasma. Beyond its product offerings, ImmunoVision provides valuable services such as microtiter plate coating, custom purification, and assay development. Its client base spans biotech firms, pharmaceutical companies, and contract research organizations. As an integral part of the Calbiotech family, ImmunoVision is dedicated to serving the global research community through an established network of distributors.
How much funding has Diamedix raised?
Diamedix has raised a total of $150K across 1 funding round:
Debt
$150K
Debt (2020): $150K with participation from PPP
What's next for Diamedix?
The recent major strategic investment in Diamedix signals a pivotal moment for the company, suggesting an accelerated trajectory for growth and market penetration. With its established expertise in autoimmune diagnostics and a broad product and service catalog, Diamedix is well-positioned to leverage this capital infusion. Future developments are likely to focus on expanding its research reagent offerings, enhancing its service capabilities, and potentially broadening its market reach through strategic partnerships or acquisitions, further solidifying its position in the competitive biotech landscape.
See full Diamedix company page
